These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 22833015)

  • 1. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
    Xue W; Wang M; Jin X; Liu H; Yao X
    Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
    Xue W; Ban Y; Liu H; Yao X
    J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435.
    Xue W; Pan D; Yang Y; Liu H; Yao X
    Antiviral Res; 2012 Jan; 93(1):126-37. PubMed ID: 22127068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
    Thibeault D; Massariol MJ; Zhao S; Welchner E; Goudreau N; Gingras R; Llinàs-Brunet M; White PW
    Biochemistry; 2009 Feb; 48(4):744-53. PubMed ID: 19119853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the drug resistance mechanism of hepatitis C virus NS3/4A to ITMN-191 due to R155K, A156V, D168A/E mutations: a computational study.
    Pan D; Xue W; Zhang W; Liu H; Yao X
    Biochim Biophys Acta; 2012 Oct; 1820(10):1526-34. PubMed ID: 22698669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The competitive binding between inhibitors and substrates of HCV NS3/4A protease: a general mechanism of drug resistance.
    Guan Y; Sun H; Li Y; Pan P; Li D; Hou T
    Antiviral Res; 2014 Mar; 103():60-70. PubMed ID: 24462696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solution structure and backbone dynamics of an engineered arginine-rich subdomain 2 of the hepatitis C virus NS3 RNA helicase.
    Liu D; Wang YS; Gesell JJ; Wyss DF
    J Mol Biol; 2001 Nov; 314(3):543-61. PubMed ID: 11846566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interdomain interface in bifunctional enzyme protein 3/4A (NS3/4A) regulates protease and helicase activities.
    Aydin C; Mukherjee S; Hanson AM; Frick DN; Schiffer CA
    Protein Sci; 2013 Dec; 22(12):1786-98. PubMed ID: 24123290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease.
    Nagpal N; Goyal S; Wahi D; Jain R; Jamal S; Singh A; Rana P; Grover A
    Gene; 2015 Oct; 570(1):115-21. PubMed ID: 26055089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors.
    Matthew AN; Zephyr J; Nageswara Rao D; Henes M; Kamran W; Kosovrasti K; Hedger AK; Lockbaum GJ; Timm J; Ali A; Kurt Yilmaz N; Schiffer CA
    mBio; 2020 Mar; 11(2):. PubMed ID: 32234812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational study on the inhibitor binding mode and allosteric regulation mechanism in hepatitis C virus NS3/4A protein.
    Xue W; Yang Y; Wang X; Liu H; Yao X
    PLoS One; 2014; 9(2):e87077. PubMed ID: 24586263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors.
    Geitmann M; Dahl G; Danielson UH
    J Mol Recognit; 2011; 24(1):60-70. PubMed ID: 21194118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
    Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
    J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.
    Hamill P; Jean F
    Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations.
    Guan Y; Sun H; Pan P; Li Y; Li D; Hou T
    Mol Biosyst; 2015 Sep; 11(9):2568-78. PubMed ID: 26219385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
    J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target.
    Schiering N; D'Arcy A; Villard F; Simic O; Kamke M; Monnet G; Hassiepen U; Svergun DI; Pulfer R; Eder J; Raman P; Bodendorf U
    Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21052-6. PubMed ID: 22160684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
    McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
    J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.